IAM
RVNC

Innovis Asset Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Innovis Asset Management’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$442K Buy
38,501
+27,984
+266% +$538K 0.17% 72
2023
Q2 		$266K Buy
+10,517
New +$328K 0.1% 129

Other funds holding RVNC

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Innovis Asset Management's RVNC Position: Q3 2023 in Review

Innovis Asset Management increased its Revance Therapeutics, Inc. (RVNC) stake by 266% in Q3 2023, buying an estimated $538K and bringing the position to 38,501 shares worth $442K. The position accounts for 0.17% of the portfolio, ranked #72.

Innovis Asset Management first reported a position in RVNC in Q2 2023 and has held it in 2 quarters since. 186 funds tracked by Wall St. Rank hold RVNC as of Q3 2023.

  • Innovis Asset Management held 38,501 shares of Revance Therapeutics, Inc. worth $442K as of Q3 2023.
  • Innovis Asset Management bought 27,984 Revance Therapeutics, Inc. shares in Q3 2023, an estimated $538K.
  • Revance Therapeutics, Inc. made up 0.17% of Innovis Asset Management's portfolio in Q3 2023, its #72 holding.
  • Innovis Asset Management first reported a position in Revance Therapeutics, Inc. in Q2 2023 and has held it in 2 quarters since.
  • 186 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2023.

Based on Innovis Asset Management's 13F filing for Q3 2023, filed 9 Nov 2023.